Web Research
Web Research — Molina Healthcare (MOH)
Bottom line up top
The filings show a company that missed and re-guided. The web shows a company under federal securities-fraud litigation over how it missed, a $40M state Medicaid-fraud settlement in Texas, and a 2026 EPS bar so low ($5.00 vs an initial 2025 guide of $24.50) that even a Q1 beat leaves the long thesis dependent on 2029 turnaround targets and a single $6B Florida contract ramp. The +37% 90-day rally has carried the stock above the average analyst target — the bounce is real, the credibility hole is not yet refilled.
What this brief contains
Ten thesis-changing findings, the news timeline behind them, a governance and insider read, the macro/policy overhang, and a reference grid of remaining specialist questions. Organised by importance, not by source.
Last Price ($)
Market Cap ($M)
90-Day Return
1-Year Return
52-Week High ($)
52-Week Low ($)
Avg Analyst Target ($)
2026 EPS Guide (≥)
Snapshot: stock close June 12, 2026; 52-week range and analyst targets from public-finance pages.
Finding 1 — The EPS collapse: $24.50 → $11.03 → $5.00 in thirteen months
This is the spine of every other web finding. Three guidance cuts in 2025 dragged FY2025 adjusted EPS from an initial guide of $24.50 (issued Feb 5, 2025, framed as 13% growth) to $11.03 actual — a 55% miss versus the company's own opening guide. Management then guided 2026 to "at least $5.00" — another ~55% step-down, blamed on Marketplace contraction and Medicare implementation costs, partly offset later in the year by the Florida CMS Kids contract ramp.
The cuts in 2025 were attributed by the CEO to a "temporary dislocation between premium rates and medical cost trend which has recently accelerated" (July 7 release). Medical Care Ratio (MCR) hit 90.4% in Q2 2025 versus the company's mid-80s long-term aim.
Red flag — So-what: A 55% miss-then-55% reset in one year resets the cost-of-capital math: any DCF built off the old long-term targets is invalid. The 2026 base is now so low that even strong percent growth off it doesn't restore the 2024 earnings power until the 2029 long-term plan plays out. Priced in? Partly — the stock is down 35% from the 2024 high of $307.77 and the FY2026 numbers are public, but the +37% 90-day rally has compressed forward P/E to ~36-40x on $5 guide and prices in a recovery the company has not yet delivered.
Sources: Reuters Oct 22 2025 · Reuters Jul 23 2025 · Fool Q4 2025 transcript · Stocktitan Q1 2026 release.
Finding 2 — Federal securities-fraud class action naming the CEO and CFO
A federal securities class action — Hindlemann v. Molina Healthcare, Inc. et al., Case No. 2:25-cv-09461, filed October 3, 2025 in the Central District of California (Judge Sherilyn Peace Garnett) — targets the company and CEO Joseph M. Zubretsky and CFO Mark L. Keim personally. Class period: February 5 — July 23, 2025. The amended complaint was filed March 31, 2026 and the action is ongoing.
The complaint alleges defendants concealed four things during the class period:
(1) material adverse facts on Molina's "medical cost trend assumptions"; (2) a "dislocation between premium rates and medical cost trend"; (3) that near-term growth depended on a "lack of utilization of behavioral health, pharmacy, and inpatient and outpatient services"; and (4) that 2025 financial guidance was substantially likely to be cut.
At least seven plaintiff firms have publicised the case (Robbins Geller, Levi & Korsinsky, Kessler Topaz, Bronstein Gewirtz, Frank R. Cruz, Rosen Law, Bleichmar Fonti & Auld). A separate derivative investigation by Grabar Law Office was announced Feb 17, 2026, examining director/officer fiduciary-duty breach.
Red flag — So-what: This is structural, multi-year overhang: discovery alone takes 18-24 months, and the named-defendant pairing of sitting CEO and CFO means any unfavourable ruling or settlement raises both directors-and-officers insurance cost and CEO-continuity risk through the 2027 retention vesting. The plaintiff theory — that management knew the medical-cost dislocation before the cuts — is a direct attack on the credibility of any forward EPS guide for the next two years. Priced in? Partially — the class period coincides with the stock's worst drawdown, and the case is on every law-firm wire — but a contested amended complaint surviving motion to dismiss (next 6-12 months) would be a fresh negative catalyst the market is not currently weighting.
Sources: Kessler Topaz case page · Levi & Korsinsky update · Robbins Geller PR · Grabar Law/AInvest Feb 18 2026.
Finding 3 — Texas Attorney General secures $40M Medicaid-fraud settlement
The Texas Office of the Attorney General's Healthcare Program Enforcement Division secured $40 million from Molina Healthcare of Texas and parent Molina Healthcare, Inc. under the Texas Health Care Program Fraud Prevention Act (THFPA). The case settled allegations that Molina failed to timely assess Medicaid beneficiaries for required services under the STAR+PLUS program (disabled, blind, or 65+) and concealed its non-compliance from Texas. The action was driven by a qui tam whistleblower.
This is not an isolated event. In 2022 Molina paid $4.6M to settle False Claims Act allegations against its former Pathways behavioral-health subsidiary in Massachusetts (unlicensed clinicians billing MassHealth). A separate Molina/GenMed Illinois nursing-home case went to the U.S. Supreme Court.
Red flag — So-what: $40M is small versus a $10B market cap, but state Medicaid contracts are won and lost on compliance reputation, not just price. STAR+PLUS is Molina's foothold in Texas — one of its most attractive long-term growth states — and a fraud-settlement on the resume changes the negotiating posture every time Molina bids a renewal. The compounding effect with the federal class action is the read: regulators and plaintiffs are both pulling on the same loose thread (medical-cost / utilization assumptions). Priced in? Mostly — the headline was absorbed without an obvious stock reaction — but contract-renewal risk in Texas is not modeled by sell-side and is a slow leak rather than an event.
Sources: Texas AG press release · Healthcare Dive on $4.6M MassHealth settlement.
Finding 4 — Q1 2026 was a real beat, but MCR is still 91.1%
On April 22, 2026, Molina reported adjusted EPS of $2.35 versus a $1.79 consensus and the stock rallied +14% the next day. Management reaffirmed the 2026 guide of premium revenue ~$42B and adjusted EPS ≥$5.00, and CEO Zubretsky said "medical cost trend was modestly favorable to our expectations."
But the underlying numbers are still degraded relative to the prior-year baseline:
Mixed signal — So-what: GAAP earnings collapsed 95% year-on-year, the MCR moved 190 bps higher not lower, and membership shrank 12%. The beat is a beat against a very lowered bar, not a return to historical earnings power. The credible read: management is at or near the trough, but the rebuild from a $2.35 quarterly run-rate to anything that justifies a multiple expansion requires several more clean prints. Priced in? Yes for the beat — the +14% one-day move captured it — but the +37% 90-day rally that followed reflects sentiment recovery and the Florida contract narrative, not Q1's fundamentals alone. Next data point: Q2 2026 print and the May 8 Investor Day 2029 targets either validate or break the bounce.
Sources: Q1 2026 release on StockTitan · Fool Q1 2026 transcript · Reuters Apr 22 2026.
Finding 5 — OBBBA Medicaid work requirements (Jan 1, 2027) hit Molina's core book
The One Big Beautiful Bill Act (2025 reconciliation law, "OBBBA") imposes mandatory work-reporting requirements on Medicaid expansion adults ages 19-64 effective January 1, 2027 — exactly where Molina's revenue concentration lives. Per KFF's April 2026 state survey, implementation pathways and exemptions are still being decided state-by-state with federal guidance lagging.
The same Act also cuts ACA premium tax credits by ~$211B over 2025-2034, materially undermining the Marketplace book Molina is already shrinking by choice. The Senate failed to pass an extension of enhanced ACA subsidies in late 2025, which is a de facto additional headwind to 2027 Marketplace economics.
Caution — So-what: Work-requirement administrative churn historically reduces Medicaid expansion enrollment 5-10% (Arkansas precedent). For Molina, even a low-single-digit erosion in expansion membership in 2027-2028 directly hits premium revenue and dilutes general-and-administrative cost leverage. The Marketplace exit (Finding 6) is partly a hedge against the ACA credit changes, but the Medicaid exposure cannot be hedged — it is the product. Priced in? Partially — the company's own 10-K risk factors flag OBBBA — but the magnitude of state-by-state implementation variance is not in consensus. This is a 2027 catalyst the market is currently discounting because Molina is delivering a 2026 beat.
Sources: KFF, "An Early Look at Policy Decisions as States Get Ready to Implement Work Requirements" (Apr 30 2026) · SHVS implementation guide · Peterson Foundation OBBBA healthcare summary.
Finding 6 — Strategic repositioning: MAPD exit, Marketplace pullback, Florida + Illinois wins
Molina is reshaping the product mix:
- MAPD exit for 2027 — recorded a ~$93M non-cash pre-tax impairment in Q1 2026 to wind down Medicare Advantage Prescription Drug; refocusing Medicare on dual-eligible D-SNP integrated products.
- Florida CMS Kids contract — ~$6B annualised premium revenue ramping late 2026, the largest growth lever in the 2026 plan.
- Illinois Medicaid Managed Care contract win — announced June 10, 2026, additive to the 2027 baseline.
- Marketplace contraction — Molina is the named exit/scaledown insurer in several state exchanges for 2026, including notable presence in Michigan and Wisconsin maps.
Positive — So-what: This is the right re-mix in the right order — fewer money-losing books, more government-Medicaid concentration with state stickiness, and a single sizeable contract (Florida) to backstop the 2026-2027 revenue line. But concentration in one contract = ramp risk: implementation costs typically run negative for two quarters before the contract is accretive, and the prior MAPD impairment is a precedent for how badly mis-priced these government deals can be. Priced in? Florida is broadly known and partly in TPs; the Illinois win helped power the late-spring rally. The hidden lever is the 2029 long-term targets unveiled at the May 8, 2026 Investor Day — that is the single document the buy-side is now underwriting.
Sources: Simply Wall St — Molina Reworks Product Mix (Apr 25 2026) · GuruFocus credit-amendment + impairment piece (Feb 7 2026) · TradingView May 8 Investor Day note · MarketScreener Illinois contract.
Finding 7 — Credit covenant amended to give running room through 2027
On February 6, 2026, Molina amended its credit agreement: a temporary reduction in the quarterly minimum interest-coverage ratio through September 2027. Separately, in November 2025 the company issued $850M of 6.5% senior notes due 2031 to refinance debt and extend maturity. Total public debt: ~$3.8B. Leverage ratio cited at ~48%.
Caution — So-what: Banks giving covenant relief mid-stress is normal but not free — it confirms that without relief the trailing-twelve-month coverage would otherwise have been at risk of breach in 2026. The 6.5% coupon is a premium coupon for an investment-grade US managed-care issuer — the marginal cost of debt re-priced higher during the crisis. None of this is balance-sheet-broken; the message is flexibility, not strength. Priced in? Credit market knows it; equity narrative has barely engaged with it. If 2027 EPS lags the recovery path, the covenant amendment will not extend further on the same terms.
Sources: GuruFocus credit-agreement amendment · AInvest on $850M notes.
Finding 8 — Insider buying — COO bought $1.56M days after the second guidance cut
The web-confirmed insider record cuts against the lawsuit's "executives knew" theory:
- COO James Woys bought 10,000 shares at $155.94 ($1.56M) on August 4, 2025 — twelve days after the July 23, 2025 second guidance cut and ~$38 stock plunge.
- CFO, COO, EVP and Chief Legal Officer all made "substantial insider purchases" during the disclosure-probe period per Simply Wall St (March 9, 2026 coverage).
- Director-level sales are tiny: Ronna Romney sold 700 shares ($107,618) Aug 6, 2025; Richard Schapiro sold 357 shares ($51,058) Nov 24, 2025; Maurice Hebert (CAO) sold 600 shares ($114,930) May 14, 2026; Jeff Barlow sold ~$3.3M May 11, 2026.
- Trailing-12-month aggregate: ~$1.56M bought / ~$3.59M sold (modest net seller, most sales tax-withholding on vesting).
- Insider ownership is only 1.44% of shares outstanding.
Positive — So-what: The Woys buy is unusually direct — open-market, sized at the manager's annual cash compensation level, taken into a falling tape and shortly before the third guidance cut. That is the behaviour of a manager who believes the trough is mis-priced, not one running for cover. It does not dispose of the class-action allegations but it complicates them, and it is a credibility datapoint that won't be visible in the filings to a less attentive reader. Priced in? Almost certainly not as a positive — the news barely registered when it landed because the dominant narrative was the cuts. This is a hidden-signal datapoint for an investor willing to underwrite the recovery thesis.
Sources: InsiderTrades.com history · Yahoo/Simply Wall St on insider buying + disclosure probe (Mar 9 2026) · Stocktitan Form 4 for Schapiro.
Finding 9 — Sell-side targets are catching up; consensus already below price
The recent target moves are all up — but the average target ($184.25) is now below the current price (~$200), which inverts the usual setup.
Zacks consensus 2026 EPS sits at $5.23 with five upward revisions in the last 60 days and none down. Stock currently at ~26x forward EPS on consensus.
Mixed — So-what: The direction of revisions (all up, none down) is the bull's best near-term argument. But the price-to-TP gap is unusual: Morgan Stanley's $167 implies ~17% downside; even Mizuho's high-end $215 implies just 7% upside. The buy-side is paying for the 2029 turnaround story; the sell-side is anchored on 2026 EPS. Priced in? Mostly. Unless a broker starts moving 2027-2028 numbers materially higher off the May 8 Investor Day, the analyst layer is more of a ceiling than a tailwind at current price.
Sources: MarketScreener news list · CNBC quote page · Zacks coverage Yahoo May 27 2026.
Finding 10 — CEO Zubretsky locked in through 2027 with performance-vesting retention grant
CEO Joseph Zubretsky (age 67 at the August 2024 amendment) signed an extended employment agreement through end-2027 that included a special one-time stock grant vesting at the end of 2027 contingent on the achievement of certain financial targets. The amendment was disclosed pre-crisis, before the medical-cost trend turned. CFO is Mark L. Keim; COO James Woys; Chairman Dale Wolf.
Mixed — So-what: The retention design is genuine alignment — vesting depends on hitting targets, not on calendar time — but those targets were set on a 2024 cost curve that has since broken. If the targets are met, the grant pays; if they are not, Molina has a 70-year-old CEO who is named in a federal securities-fraud action vesting nothing, two years from a forced succession discussion. The Glassdoor read on Zubretsky is mediocre but not toxic — 59% CEO approval, 50% would recommend on 2,747 ratings — consistent with a company in cost-discipline mode rather than crisis. Priced in? The retention is well-known; succession risk is not currently in consensus.
Sources: Molina IR — CEO contract amendment (Aug 20 2024) · Glassdoor profile · WSJ key-people page.
News timeline — last ~12 months (the reference layer)
Materiality-filtered; older events retained where the action is still live (the class action's Feb 2025 trigger event is included because the case is unresolved).
Governance and people read
Board / officers: CEO Joseph M. Zubretsky (President & CEO since Nov 2017, contract through end-2027), CFO Mark L. Keim, COO James E. Woys, Chairman Dale Wolf, named directors include Ronna Romney, Richard Zoretic, Leo Grohowski, Barbara Brasier, Steven Orlando, Francis Soistman, Richard Schapiro.
Insider ownership 1.44% — typical for a manager-not-founder-led large-cap insurer. The Molina family founders are no longer in operating roles (Dr C. David Molina, the founder, died in 1996; sons J. Mario Molina and John C. Molina departed in 2017 when Zubretsky was hired). The company's own filings list "negative public perceptions of the Medicaid program created by, the One Big Beautiful Bill Act" as a risk factor.
Insider behaviour 12-month:
- $1.56M open-market purchases (COO Woys, the standout)
- $3.59M sales (largely tax-withholding on equity-vesting events; one larger Barlow sale May 2026)
- Two director micro-sales (~$50-100K each) — not signal-bearing
- Sentiment: net buyer once tax-withholding effects are stripped out despite the share-count flow showing a small net seller
Employee culture (Glassdoor): 3.3/5 over 2,747 ratings; 50% recommend to a friend; 59% CEO approval; mission language consistent with stated strategy. Indeed salary distribution is consistent with a regulated, scaled managed-care employer.
Governance flags: A live federal securities class action naming sitting CEO + CFO is the single biggest governance overhang. The Feb 2026 covenant relief plus the $850M premium-coupon issuance are credit-side governance signals — the board is comfortable accepting more expensive debt and softer covenants rather than diluting equity at the lows.
Industry / macro overlay — new external evidence
Industry-side findings that go beyond the dedicated Industry tab:
- OBBBA work-requirement implementation is the 2027 cliff. State-by-state variance in pathways, exemptions, and IT readiness will determine the actual enrollment hit. (KFF Apr 30 2026 survey.)
- CMS finalised tougher oversight for accrediting organisations (Modern Healthcare, June 2026) — compliance-burden uplift across managed care.
- Judge struck the federal rule shortening ACA enrollment and tightening eligibility checks — short-term tailwind to Marketplace volumes but the underlying OBBBA premium-tax-credit reductions ($211B / 2025-2034) remain.
- Marketplace insurer entries/exits 2026: Aetna re-entering aggressively in 14 states; Molina noted as continuing in Michigan and Wisconsin. Marketplace is a contested book where Molina has chosen to shrink rather than fight.
- State Medicaid procurement cycle live for 2027 — Illinois already awarded (to Molina, June 10 2026); California Medi-Cal procurement among the next watch items.
The honest read: the industry context does not contradict the bull case (Medicaid is structurally needed, contracts are sticky, Florida is real), but it adds a 2027 risk layer the May 8 Investor Day did not eliminate.
Specialist-question reference grid (collapsed)
These are the 35 specialist queries posed across Industry, Warren, Quant, Forensic, Sherlock, Historian, Moat, Competition, and Tech. The ones that changed the thesis are already promoted into Findings 1-10 above. The remainder are summarised here for completeness — one-line answers with source pointers.
What the web does not contradict
It is worth marking the things the web evidence broadly confirms about the filings, because the absence of contradiction is itself a finding:
- The premium-revenue scale ($42B 2026 guide) and the Medicaid-centric mix are confirmed across multiple independent sources.
- The Florida CMS Kids contract magnitude (~$6B annualised) is confirmed in multiple investor-day summaries and press notes.
- The $93M MAPD-exit impairment matches the 8-K and was reported consistently.
- Capital structure (~$3.8B public debt, the $850M / 6.5% notes due 2031) reconciles to the bond databases.
What the web adds that the filings would not surface as crisply: the severity of the legal overhang, the timing of the COO's open-market buy relative to the second guidance cut, and the policy clock on OBBBA work requirements — all three of which are above.